S&P 500
(1.37%) 5 133.67 points
Dow Jones
(1.29%) 38 718 points
Nasdaq
(2.13%) 16 178 points
Oil
(-0.77%) $78.34
Gas
(4.96%) $2.14
Gold
(0.07%) $2 311.30
Silver
(-0.47%) $26.70
Platinum
(0.33%) $965.75
USD/EUR
(-0.36%) $0.929
USD/NOK
(-1.19%) $10.86
USD/GBP
(-0.12%) $0.797
USD/RUB
(0.37%) $91.47

Aktualne aktualizacje dla Viking Therapeutics Inc [VKTX]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
BUY
57.14%
return 7.81%
SELL
39.58%
return -81.32%
Ostatnio aktualizowano3 geg. 2024 @ 21:11

2.31% $ 77.51

SPRZEDAż 157 min ago

@ $76.59

Wydano: 3 geg. 2024 @ 18:33


Zwrot: 1.21%


Poprzedni sygnał: geg. 2 - 20:44


Poprzedni sygnał: Kupno


Zwrot: 1.55 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 21:11):

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders...

Stats
Dzisiejszy wolumen 2.65M
Średni wolumen 6.51M
Kapitalizacja rynkowa 8.55B
EPS $-0.250 ( 2024-04-24 )
Następna data zysków ( $-0.250 ) 2024-07-24
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -84.25
ATR14 $4.80 (6.20%)
Insider Trading
Date Person Action Amount type
2024-05-01 Mancini Marianna Buy 51 000 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Sell 23 746 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Sell 26 142 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Buy 35 426 Common Stock, par value $0.00001 per share
2024-05-01 Mancini Marianna Buy 90 000 Common Stock, par value $0.00001 per share
INSIDER POWER
1.01
Last 100 transactions
Buy: 2 844 296 | Sell: 2 903 733

Wolumen Korelacja

Długi: 0.81 (strong)
Krótki: 0.47 (neutral)
Signal:(62) Neutral

Viking Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
CFFE0.97
ARIZ0.966
EMLD0.96
ARTEU0.96
AIB0.958
GENQ0.956
FTII0.956
ABST0.955
GDST0.955
KIN0.954
10 Najbardziej negatywne korelacje
SMFL-0.968
CYAN-0.963
MYSZ-0.96
PIII-0.958
CREG-0.955
BCAB-0.95
PYR-0.95
SPCX-0.949
KTTA-0.948
VFF-0.947

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Viking Therapeutics Inc Korelacja - Waluta/Towar

The country flag 0.42
( neutral )
The country flag 0.72
( moderate )
The country flag 0.00
( neutral )
The country flag 0.24
( neutral )
The country flag 0.52
( weak )
The country flag -0.61
( weak negative )

Viking Therapeutics Inc Finanse

Annual 2023
Przychody: $0
Zysk brutto: $-292 000 (0.00 %)
EPS: $-0.910
FY 2023
Przychody: $0
Zysk brutto: $-292 000 (0.00 %)
EPS: $-0.910
FY 2022
Przychody: $0
Zysk brutto: $-291 000 (0.00 %)
EPS: $-0.880
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-0.757

Financial Reports:

No articles found.

Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej